A review of possible therapies for Parkinson’s disease

Alexander, 2004, Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder, Dialogues Clin Neurosci, 6, 259, 10.31887/DCNS.2004.6.3/galexander Haddad, 2018, Dopamine and levodopa prodrugs for the treatment of Parkinson’s disease, Molecules, 23, 1 Asanuma, 2003, Dopamine or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease, Neurotoxicol Res, 5, 165, 10.1007/BF03033137 Stoker, 2018, Emerging treatment approaches for Parkinson’s disease, Front Neurosci, 12, 693, 10.3389/fnins.2018.00693 Marsden, 1994, Problems with long-term levodopa therapy for Parkinson's disease, Clin Neuropharmacol, 17, S32 Teo, 2013, Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease, Transl Neurodegener, 2, 19, 10.1186/2047-9158-2-19 Rivest, 1999, COMT inhibitors in Pakinson’s disease, Can J Neurol Sci, 26, S34, 10.1017/S031716710000007X Wang, 2017, A meta-analysis of adenosine A2A receptor antagonists on Levodopa-induced dyskinesia in vivo, Front Neurol, 8, 702, 10.3389/fneur.2017.00702 Deuschl, 2006, A randomized trial of deep brain stimulation for Parkinson’s disease, N Engl J Med, 355, 896, 10.1056/NEJMoa060281 Schuepbach, 2013, Neurostimulation for Parkinson’s disease with early motor complications, N Engl J Med, 368, 610, 10.1056/NEJMoa1205158 Barbe, 2014, Timmermann L Multiple source current steering–a novel deep brain stimulation concept for customized programming in a Parkinson’s disease patient, Parkinsonism Relat Disord, 20, 471, 10.1016/j.parkreldis.2013.07.021 Timmermann, 2016, 155 McIntyre, 2016, Deep brain stimulation mechanisms: the control of network activity via neurochemistry modulation, J Neurochem, 139, 338, 10.1111/jnc.13649 Gaillard, 2011, (2011) Rewiring the brain with cell transplantation in Parkinson’s disease, Trends Neurosci, 34, 124, 10.1016/j.tins.2011.01.003 Kirkeby, 2012, Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions, Cell Rep, 1, 703, 10.1016/j.celrep.2012.04.009 Yang, 2014, Activated astrocytes enhance the dopaminergic differentiation of stem cells and promote brain repair through bFGF, Nat Commun, 5, 5627, 10.1038/ncomms6627 Christophersen, 2006, Induction of dopaminergic neurons from growth factor expanded neural stem/progenitor cell cultures derived from human first trimester forebrain, Brain Res Bull, 70, 457, 10.1016/j.brainresbull.2006.07.001 Knoepfler, 2009, Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine, Stem Cells, 27, 1050, 10.1002/stem.37 Medvedev, 2010, Induced pluripotent stem cells: problems and advantages when applying them in regenerative medicine, Acta Nat, 2, 18, 10.32607/20758251-2010-2-2-18-27 Lim, 2015, Noggin over-expressing mouse embryonic fibroblasts and ms5 stromal cells enhance directed differentiation of dopaminergic neurons from human embryonic stem cells, PLoS One, 10, 10.1371/journal.pone.0138460 Costin, 2007, Human skin pigmentation: melanocytes modulate skin color in response to stress, FASEB J, 21, 976, 10.1096/fj.06-6649rev Rios, 1999, Catecholamine synthesis is mediated by tyrosinase in the absence of tyrosine hydroxylase, J Neurosci, 19, 3519, 10.1523/JNEUROSCI.19-09-03519.1999 Asanuma, 2013, Transplantation of melanocytes obtained from the skin ameliorates apomorphine-induced abnormal behavior in rodent hemi-Parkinsonian models, PLoS One, 8, 10.1371/journal.pone.0065983 Zhang, 2016, Two-step production of monoamines in monoenzymatic cells in the spinal cord: a different control strategy of neurotransmitter supply?, Neural Regen Res, 11, 1904, 10.4103/1673-5374.197124 Keber, 2015, Striatal tyrosine hydroxylase-positive neurons are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice, Neuroscience, 298, 302, 10.1016/j.neuroscience.2015.04.021 Colette Daubner, 2011, Tyrosine hydroxylase and regulation of dopamine synthesis, Arch Biochem Biophys, 508, 1, 10.1016/j.abb.2010.12.017 German, 2015, Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease, Pharmacol Rev, 67, 1005, 10.1124/pr.114.010397 Spillantini, 1997, Alpha-synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 Polymeropoulos, 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease, Science, 276, 2045, 10.1126/science.276.5321.2045 Hernandez, 2016, Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance, J Neurochem, 139, 59, 10.1111/jnc.13593 Schulte, 2011, Genetic basis of Parkinson’s disease: inheritance, penetrance, and expression, Appl Clin Genet, 4, 67 Le, 2008, Decreased NURR1 gene expression in patients with Parkinson’s disease, J Neurol Sci, 273, 29, 10.1016/j.jns.2008.06.007 Oh, 2016, Combined Nurr1 and Foxa2 roles in the therapy of Parkinson’s disease, EMBO Mol Med, 8, 171, 10.15252/emmm.201506162 Dong, 2016, Nurr1-based therapies for Parkinson’s disease, CNS Neurosci Ther, 22, 351, 10.1111/cns.12536 Healy, 2008, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study, Lancet Neurol, 7, 583, 10.1016/S1474-4422(08)70117-0 Kang, 2017, Leucine-rich repeat kinase 2 and Parkinson’s disease, Proteomics, 17, 1, 10.1002/pmic.201600092 Follett, 2016, Parkinson disease-linked Vps35 R524W mutation impairs the endosomal association of retromer and induces alpha-synuclein aggregation, J Biol Chem, 291, 18283, 10.1074/jbc.M115.703157 Girard, 2005, The DnaJ-domain protein RME-8 functions in endosomal trafficking, J Biol Chem, 280, 40135, 10.1074/jbc.M505036200 Gustavsson, 2015, DNAJC13 genetic variants in parkinsonism, Mov Disord, 30, 273, 10.1002/mds.26064 Schrag, 2006, Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism, Lancet Neurol, 5, 355, 10.1016/S1474-4422(06)70411-2 Lucking, 2000, Association between early-onset Parkinson’s disease and mutations in the parkin gene, N Engl J Med, 342, 1560, 10.1056/NEJM200005253422103 Kang, 2017 Ledford, 2015, CRISPR, the disruptor, Nature, 522, 20, 10.1038/522020a Schenk, 2017, First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers, Mov Disord, 32, 211, 10.1002/mds.26878 Schneeberger, 2016, Active immunization therapies for Parkinson's disease and multiple system atrophy, Mov Disord, 31, 214, 10.1002/mds.26377 Manfredsson, 2018, Challenges in passive immunization strategies to treat Parkinson disease, JAMA Neurol, 75, 1180, 10.1001/jamaneurol.2018.0346 Martínez-Fernández, 2016, The hidden sister of motor fluctuations in Parkinson’s disease: a review on nonmotor fluctuations, Mov Disord, 31, 1080, 10.1002/mds.26731 LaHue, 2016, The best medicine? The influence of physical activity and inactivity on Parkinson’s disease, Mov Disord, 31, 1444, 10.1002/mds.26728 Antelmi, 2017, Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep behavior disorder, Neurology, 88, 2128, 10.1212/WNL.0000000000003989 Doppler, 2017, Dermal phospho-alpha-synuclein deposits confirm REM sleep behavior disorder as prodromal Parkinson's disease, Acta Neuropathol, 133, 535, 10.1007/s00401-017-1684-z Meles, 2017, FDG PET, dopamine transporter SPECT, and olfaction: combining biomarkers in REM sleep behavior disorder, Mov Disord, 32, 1482, 10.1002/mds.27094